Anti-MAML1 / Mastermind-like protein 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. MAML1 antibody detects Mastermind-like protein 1, a transcriptional coactivator that plays a key role in the Notch signaling pathway, which regulates cell fate determination, differentiation, and proliferation. Encoded by the MAML1 gene on chromosome 5q35.3, this nuclear protein acts as a core component of the Notch transcriptional activation complex. Upon Notch receptor activation and nuclear translocation of the Notch intracellular domain (NICD), MAML1 binds NICD and the transcription factor CSL (CBF1/RBPJ), forming a ternary complex that recruits additional coactivators to initiate target gene transcription.MAML1 contains an N-terminal basic domain responsible for binding NICD and CSL, a central acidic transcriptional activation domain, and a C-terminal domain that mediates interactions with additional transcription factors and coactivators such as p300/CBP. Through these interactions, MAML1 promotes transcription of Notch target genes including HES1, HEY1, and MYC, which are involved in cell differentiation and proliferation. Because Notch signaling is crucial for tissue development and homeostasis, MAML1 serves as a master regulator of developmental pathways across multiple cell types, including neural, hematopoietic, and epithelial lineages.The MAML1 antibody is widely used in molecular biology, developmental biology, and cancer research to assess Notch pathway activation and transcriptional regulation. Western blot analysis typically identifies a 115 kilodalton band corresponding to MAML1, while immunofluorescence reveals nuclear localization that overlaps with Notch pathway components. This antibody enables the study of transcriptional coactivation events and gene regulation in Notch-mediated signaling contexts.Beyond Notch signaling, MAML1 also functions as a coactivator for other transcriptional regulators such as MEF2C, p53, and beta-catenin, broadening its impact on gene networks related to cell growth and apoptosis. Dysregulation of MAML1 has been linked to oncogenic transformation, particularly in leukemia, glioma, and breast cancer, where aberrant Notch signaling drives uncontrolled proliferation. The MAML1 antibody provides a reliable tool for investigating transcriptional complexes and signaling crosstalk mechanisms. NSJ Bioreagents offers this antibody validated for its applications, ensuring reproducibility and specificity for transcriptional and signaling studies.